Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.

Atherosclerosis. Supplements - 1 May 2015

Artemeva N V, Safarova M S, Ezhov M V, Afanasieva O I, Dmitrieva O A, Pokrovsky S N

Abstract excerpt

BACKGROUND: Lipoprotein(a) [Lp(a)] is a cardiovascular risk factor; in addition to being a low-density lipoprotein (LDL)-like particle, it contains highly heterogeneous apolipoprotein(a) [apo(a)]. No prior studies have evaluated extended-release (ER) niacin effect on Lp(a) level depending on apo(...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoprotein(a)
Share to Hyperlipoproteinemias
Share to Hypolipidemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoprotein(a)

Share to Molecular Weight

Share to Niacin

Share to Patient Selection

Share to Russia

Source

Identifiers

PMID: 25936305
DOI: 10.1016/j.atherosclerosissup.2015.02.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-25936305-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.PMID 25936305Read ↗

Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular DiseaseSemantic proximity Read ↗

VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.Semantic proximity Read ↗

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.Semantic proximity Read ↗

Non-genetic influences on lipoprotein(a) concentrationsSemantic proximity Read ↗

Lipoprotein(a) and coronary heart disease.Semantic proximity Read ↗

Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.Semantic proximity Read ↗

[Lipoprotein (a)].Semantic proximity Read ↗

Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone.Semantic proximity Read ↗

Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.Semantic proximity Read ↗

Interactions among Lp(a) phenotypes, Lp(a) concentrations and lipoprotein response to fat-modified dietsSemantic proximity Read ↗

Association of dietary niacin intake with all-cause and cardiovascular mortality in the general populationSemantic proximity Read ↗

Apo A-IV: an update on regulation and physiologic functions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.